Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

zoetis hungary kft. - escherichia coli, strain s1091/83, fimbrial adhesin f5 and f41, inacti, szarvasmarhacorona-vírus bovine coronavirus, strain 800, inactivated, szarvasmarharota-vírus bovine rotavirus, strain 1005/78, inactivated, bovine rotavirus, strain holland, inactivated - szuszpenziós injekció - inactivated bovine rotavirus vaccine + inactivated bovine coronavirus - szarvasmarha

Európai Unió - magyar - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumabot - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunszuppresszánsok - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

elanco animal health gmbh - toltrazuril - belsoleges oldat - toltrazuril - házityúk, pulyka

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

bestgroom kft. - diklazuril - külsoleges oldat - diclazuril - kutya, macska

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

elanco animal health gmbh - toltrazuril - belsoleges szuszpenzió - toltrazuril - szarvasmarha, juh, sertés

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

laboratorios hipra s.a. - clostridium novyi, escherichia coli, clostridium perfringens - szuszpenziós injekció - escherichia vaccine + clostridium vaccine - sertés

Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sanofi pasteur sa - vakcina (virális) -

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

pharma vim kft. - trimetoprim, szulfadimetoxin-nátrium - por belsoleges oldathoz - sulfadimethoxine and trimethoprim - házi nyúl, házityúk

Európai Unió - magyar - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - rekombináns hólyagos szájgyulladás vírus (törzs indiana) a törlési a boríték glikoprotein, helyébe a zaire ebolavirus (törzs kikwit 1995) felszíni glikoprotein - vérzéses láz, ebola - a vakcinák - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. a használata ervebo összhangban kell lennie a hivatalos ajánlások.

Európai Unió - magyar - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunológiai készítmények suidae számára - sertések (hizlaló) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.